Study Population

Seropositive CMV-IgM (%)

Equivocal

Positive

Negative

Recipients (n = 40)

9 (22.5%)

29 (72.5%)

2 (5%)

Use of CMV Prophylaxis

Acyclovir

Ganciclovir

No Prophylaxis

Recipients (n = 40)

15 (37.5%)

1 (2.5%)

24 (60%)

Immunosuppressive Regimen

Number of Recipients (%)

n = 40

CPA

14 (35%)

CPM

22 (55%)

Others*

4 (10%)

Acute rejection episodes

Yes

20 (50%)

No

20 (50%)